Tranexamic Acid in Older Patients with Hip Fracture and Recent Nonacute Ischaemic Stroke: A Historical Control Cohort Study

Imagine you are a mechanic trying to fix a car that's been in a crash. The car is old, the engine is sputtering, and there's a massive oil leak. In the world of medicine, this "car" is an elderly person who has broken their hip, and the "oil leak" is the blood loss that happens when the bone breaks and when surgeons operate to fix it. Doctors have a special tool called Tranexamic Acid (TXA). Think of TXA as a super-strong "stop-leak" patch for the body's blood vessels. It works by telling the body's natural clot-dissolving system to take a break, so the blood clots stay solid and stop the bleeding.

However, there's a catch. Some of these "cars" have a history of a different kind of trouble: a stroke. A stroke happens when a blood vessel in the brain gets clogged. Because TXA helps blood clot, doctors have been terrified that using it might cause a new clog, leading to another stroke or a heart attack. It's like being afraid that the "stop-leak" patch might accidentally glue the car's engine parts together. This fear has left many elderly patients with hip fractures and a history of stroke in a medical "grey zone": they need the patch to stop the bleeding, but doctors worry the patch might cause a new disaster. This study steps into that grey zone to see if the patch is actually safe and if it works differently depending on where the car broke.

---

The Big Experiment: Patching the "Cars"

Researchers at Beijing Tongren Hospital decided to look back at the records of 843 older patients (average age around 80) who had broken their hips and had a history of a stroke that happened within the last year, but wasn't happening right now (it was "stable"). They split these patients into two groups based on a simple rule: did they get the "stop-leak" patch (TXA) during surgery, or did they not?

The doctors were looking for two main things:

1. Did the patch stop the bleeding? (Did they lose less blood and need fewer blood transfusions?)
2. Did the patch cause a new disaster? (Did more people have a new stroke, heart attack, or blood clots in their legs within a year?)

The Results: It Depends on the Type of Break

The study found that the answer to "Does it work?" depends entirely on the shape of the broken bone. The researchers looked at two types of hip fractures: Femoral Neck (the break is right inside the hip joint capsule) and Intertrochanteric (the break is lower down, in a spongy, highly vascular area).

1. The "Femoral Neck" Break: A Clear Win
For the patients with femoral neck fractures, the TXA patch worked like a charm.

• The Bleeding: Patients who got TXA lost significantly less blood during the surgery.
• The Transfusions: They were much less likely to need a blood transfusion. In fact, 56.2% of the TXA group needed blood, compared to 69.4% of the group that didn't get the drug.
• The Volume: When they did need blood, they needed less of it. The TXA group got a median of 2 units of blood, while the control group got 4 units.
• The Safety: Crucially, zero extra trouble happened. The rates of new strokes, heart attacks, or leg clots were exactly the same as the group that didn't get the drug.

2. The "Intertrochanteric" Break: A Mixed Bag
For the patients with intertrochanteric fractures, the story was different.

• The Bleeding: The TXA group did lose slightly less blood during the actual surgery (a median of 100 mL vs. 120 mL).
• The Transfusions: However, the drug did not stop them from needing blood transfusions. The rate of transfusions was almost identical (56.7% for TXA vs. 59.5% for the control group), and the amount of blood they needed was the same.
• The Safety: Just like the other group, there was no increase in strokes, heart attacks, or clots. The drug was safe, but it just didn't do enough to change the transfusion numbers.

Why the Difference? The "Hidden Leak" Theory

The researchers have a clever explanation for why the drug worked for one type of break but not the other.

Think of a Femoral Neck fracture like a pipe bursting inside a sealed room. Most of the blood loss happens during the surgery when the surgeons are working inside that room. Since the drug was given right before the surgery started, it was there to plug the hole exactly when the leak was happening.

Think of an Intertrochanteric fracture like a pipe bursting in a swampy, spongy forest. A huge amount of blood leaks out immediately when the bone breaks, long before the ambulance even arrives. By the time the surgeons get there and give the drug, a massive amount of blood has already been lost into the "swamp" (the body's tissues). The drug can stop the new bleeding during the operation, but it can't suck the blood back out of the swamp or fix the damage that happened before the surgery started. That's why the transfusion numbers didn't change much for this group.

The Bottom Line: No New Disasters

The most important finding of this paper is the safety report. For a long time, doctors were worried that giving this "clot-stopping" drug to stroke survivors would cause another stroke. This study suggests that for older patients with a stable, non-acute stroke (one that happened in the last year but isn't currently active), giving TXA during hip surgery does not increase the risk of a new stroke, heart attack, or death within a year.

The study concludes that TXA is a safe and effective tool for these patients, but doctors should adjust their expectations based on the type of fracture. If the break is a femoral neck fracture, the drug is a powerful ally that saves blood. If it's an intertrochanteric fracture, the drug is still safe, but it might not be enough to stop the need for blood transfusions because the "hidden leak" happens too early. The researchers suggest that for the second type of break, we might need to think about giving the drug earlier or using other strategies, but for now, we know it's safe to use even in patients with a history of stroke.